All In MedTech

FDA Clearance Tracker · P910007-S007

ABBOTT ARCHITECT TOTAL PSA

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 2, 2004 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 2, 2004

Approved

Time to decision

789 days

Received Dec 5, 2001. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P910007-S007
Device name
ABBOTT ARCHITECT TOTAL PSA
Applicant location
Abbott Park, IL
Received
Dec 5, 2001
Decided
Feb 2, 2004
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P910007

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ABBOTT ARCHITECT TOTAL PSA ASSAY. THE ARCHITECT TOTAL PSA ASSAY IS INDICATED: 1) AS AN AID IN THE DETECTION OF PROSTATE CANCER WHEN USED IN CONJUNCTION WITH DIGITAL RECTAL EXAM (DRE) IN MEN 50 YEARS OR OLDER. PROSTATE BIOPSY IS REQUIRED FOR DIAGNOSIS OF CANCER. 2) AS AN ADJUNCTIVE TEST TO AID IN THE MANAGEMENT OF PROSTATE CANCER PATIENTS.

Source documents

Other decisions for Abbott Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.